JLJaila Dias Borges Lalwani

Jaila Dias Borges Lalwani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaila Dias Borges Lalwani has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A covid-19 leve tem impacto na capacidade para o trabalho?

    by Sylvia Correia de Almeida, Tiótrefis Gomes Fernandes, Guilherme Peixoto Tinoco Arêas, Jaila Dias Borges Lalwani, Pritesh Lalwani, Thaís Sant’aNna

    RESUMO Este estudo transversal comparou a capacidade para o trabalho entre indivíduos acometidos e não acometidos pela covid-19 leve. Os participantes realizaram exame sorológico para SARS-CoV-2 e responderam ao questionário Índice de Capacidade para o Trabalho. O grupo soropositivo apresentou menor escore final do ICT em comparação com o grupo soronegativo (40 [36-44] vs 43 [38-45]; p=0,008). A presença de 3 ou mais lesões/doenças atuais (RP=3,23; IC 95%:1,59-6,54; p<0,0001) e o sexo feminino (RP=3,28; IC 95%:1,27-8,46; p=0,014) foram fatores determinantes para menor capacidade laboral no grupo soropositivo. Concluiu-se que, apesar dos indivíduos que tiveram covid-19 leve apresentarem menor capacidade para o trabalho, a doença não foi fator determinante para esse desfecho.

  • Open Access

    Does mild COVID-19 impact work ability?

    by Sylvia Correia de Almeida, Tiótrefis Gomes Fernandes, Guilherme Peixoto Tinoco Arêas, Jaila Dias Borges Lalwani, Pritesh Lalwani, Thaís Sant’aNna

    This cross-sectional study compared work ability between individuals affected and not affected by mild COVID-19. The participants underwent serological testing for SARS-CoV-2 and answered the Work Ability Index (WAI) questionnaire. The seropositive group had a lower final WAI score compared to the seronegative group (40 [36–44] vs 43 [38–45]; p=0.008). The presence of three or more current injuries/diseases (PR=3.23; 95%CI:1.59-6.54; p<0.0001) and female sex (PR=3.28; 95%CI:1.27–8.46; p=0.014) were determining factors for lower work ability in the seropositive group. Work ability was poorer in individuals who had mild COVID-19, although the disease was not a determining factor for this decrease.

  • Perceived fatigue and functional status after mild symptomatic and asymptomatic COVID-19

    by Thaís Sant’aNna, Guilherme Peixoto Tinoco Arêas, Kéren Libório Neves, Pritesh Lalwani, Jaila Dias Borges Lalwani, Tiótrefis Gomes Fernandes

  • Open Access

    Hybrid Immunity Results in Enhanced and More Sustained Antibody Responses after the Second Sinovac-CoronaVac Dose in a Brazilian Cohort: DETECTCoV-19 Cohort

    by Bárbara Batista Salgado, Aguyda Rayany Cavalcante Barbosa, Ana Ruth Arcanjo, Daniel Barros de Castro, Tatyana Costa Amorim Ramos, Felipe Naveca, Daniel M. Altmann, Rosemary J. Boyton, Jaila Dias Borges Lalwani, Pritesh Lalwani

    We measured anti-SARS-CoV-2 antibody responses before and after CoronaVac (inactivated) vaccination in a case–control study performed in CoronaVac-immunized individuals participating in a longitudinal prospective study of adults in Manaus (DETECTCoV-19). Antibody responses were measured by standard serological immunoassays. Peak anti-S-RBD and neutralizing RBD-ACE2 blocking antibody responses after two doses of CoronaVac vaccine were similar in vaccine breakthrough cases (n = 9) and matched controls (n = 45). Individuals with hybrid immunity resulting from prior SARS-CoV-2 infection followed by vaccination (n = 22) had elevated levels of anti-N, anti-S-RBD and RBD-ACE2 blocking antibodies after the second vaccine dose compared to infection-naïve individuals (n = 48). Post-vaccination SARS-CoV-2-specific antibody responses rapidly waned in infection-naïve individuals. Antibody responses wane after vaccination, making individuals susceptible to infection by SARS-CoV-2 variants. These findings support the need for booster doses after primary vaccination. Population antibody serosurveys provide critical information toward implementing optimal timing of booster doses.


  • Open Access

    Antigen-Specific Antibody Signature Is Associated with COVID-19 Outcome

    by Bárbara Batista Salgado, Maele Ferreira Jordão, Thiago Barros Do Nascimento de Morais, Danielle Severino Sena da Silva, Ivanildo Vieira Pereira Filho, Wlademir Braga Salgado Sobrinho, Nani Oliveira Carvalho, Rafaella Oliveira dos Santos, Julia Forato, Priscilla Paschoal Barbosa, et al.

    Numerous studies have focused on inflammation-related markers to understand COVID-19. In this study, we performed a comparative analysis of spike (S) and nucleocapsid (N) protein-specific IgA, total IgG and IgG subclass response in COVID-19 patients and compared this to their disease outcome. We observed that the SARS-CoV-2 infection elicits a robust IgA and IgG response against the N-terminal (N1) and C-terminal (N3) region of the N protein, whereas we failed to detect IgA antibodies and observed a weak IgG response against the disordered linker region (N2) in COVID-19 patients. N and S protein-specific IgG1, IgG2 and IgG3 response was significantly elevated in hospitalized patients with severe disease compared to outpatients with non-severe disease. IgA and total IgG antibody reactivity gradually increased after the first week of symptoms. Magnitude of RBD-ACE2 blocking antibodies identified in a competitive assay and neutralizing antibodies detected by PRNT assay correlated with disease severity. Generally, the IgA and total IgG response between the discharged and deceased COVID-19 patients was similar. However, significant differences in the ratio of IgG subclass antibodies were observed between discharged and deceased patients, especially towards the disordered linker region of the N protein. Overall, SARS-CoV-2 infection is linked to an elevated blood antibody response in severe patients compared to non-severe patients. Monitoring of antigen-specific serological response could be an important tool to accompany disease progression and improve outcomes.


  • Open Access

    An Electrochemical Immunosensor Based on Carboxylated Graphene/SPCE for IgG-SARS-CoV-2 Nucleocapsid Determination

    by Luciana de Souza Freire, Camila Macena Ruzo, Bárbara Batista Salgado, Ariamna María Dip Gandarilla, Yonny Romaguera-Barcelay, Ana P. M. Tavares, Maria Goreti Ferreira Sales, Isabelle Cordeiro, Jaila Dias Borges Lalwani, Robert Matos, et al.

    The COVID-19 pandemic has emphasized the importance and urgent need for rapid and accurate diagnostic tests for detecting and screening this infection. Our proposal was to develop a biosensor based on an ELISA immunoassay for monitoring antibodies against SARS-CoV-2 in human serum samples. The nucleocapsid protein (N protein) from SARS-CoV-2 was employed as a specific receptor for the detection of SARS-CoV-2 nucleocapsid immunoglobulin G. N protein was immobilized on the surface of a screen-printed carbon electrode (SPCE) modified with carboxylated graphene (CG). The percentage of IgG-SARS-CoV-2 nucleocapsid present was quantified using a secondary antibody labeled with horseradish peroxidase (HRP) (anti-IgG-HRP) catalyzed using 3,3′,5,5′-tetramethylbenzidine (TMB) mediator by chronoamperometry. A linear response was obtained in the range of 1:1000–1:200 v/v in phosphate buffer solution (PBS), and the detection limit calculated was 1:4947 v/v. The chronoamperometric method showed electrical signals directly proportional to antibody concentrations due to antigen-antibody (Ag-Ab) specific and stable binding reaction.


  • Open Access

    Electrochemical Immunosensor Based on Carboxylated Graphene/SPCE for Igg-SARS-Cov-2 Nucleocapsid Determination

    by Walter Brito, Luciana Freire, Camila Ruzo, Bárbara Salgado, Ariamna María Dip Gandarilla, Yonny Romaguera-Barcelay, Ana Tavares, Maria Goreti Ferreira Sales, Isabelle Cordeiro, Jaila Lalwani, et al.

    The COVID-19 pandemic has highlighted the importance and urgent need of rapid and accurate diagnostic tests for detection and screening of this infection. In our proposal, a biosensor based on the ELISA immunoassay was developed for monitoring antibodies against SARS-CoV-2 in human serum samples. The SARS-CoV-2 nucleocapsid protein (N-protein) was selected as a specific receptor for the detection of SARS-CoV-2 nucleocapsid immunoglobulin G. Thus, the N-protein was immobilized on surface of screen-printed carbon electrode (SPCE) modified with carboxylated graphene (CG). The IgG-SARS-CoV-2 nucleocapsid concentration was quantified using a secondary antibody labelled with horseradish peroxidase (HRP) (anti-IgG-HRP) catalyzed by 3,3’,5,5’-tetramethylbenzidine (TMB) mediator by chronoamperometry. A linear response was obtained in the range of 1:1000-1:200 v/v in phosphate buffer solution (PBS) and the limit of detection calculated was of 1:4947 v/v. The chronoamperometric method showed electrical signals directly proportional to antibody concentrations due to Ag-Ab specific and stable binding reaction.

  • Open Access

    High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort

    by Pritesh Lalwani, Roger V Araujo-Castillo, Christian A Ganoza, Bárbara Batista Salgado, Ivanildo Vieira Pereira Filho, Danielle Severino Sena da Silva, Thiago Barros Do Nascimento de Morais, Maele Ferreira Jordão, Jessica Vanina Ortiz, Aguyda Rayany Cavalcante Barbosa, et al.


  • Open Access

    SARS-CoV-2 seroprevalence and associated factors in Manaus, Brazil: baseline results from the DETECTCoV-19 cohort study

    by Pritesh Lalwani, Bárbara Batista Salgado, Ivanildo Vieira Pereira Filho, Danielle Severino Sena da Silva, Thiago Barros Do Nascimento de Morais, Maele Ferreira Jordão, Aguyda Rayany Cavalcante Barbosa, Isabelle Bezerra Cordeiro, Júlio Nino de Souza Neto, Enedina Nogueira de Assunção, et al.